[약업신문]BNC Korea, Taiwan Golden Biotech Co., Ltd.

On January 4th, BNC Korea Co., Ltd. announced that it has signed an exclusive marketing, promotion, distribution, sales and manufacturing contract with Taiwan’s Golden Biotech Co., Ltd. for the COVID-19 treatment candidate’ntroquinonol’ (product name: Hocena) in Russia, Turkey, Ukraine and Korea.

As a result of negotiating about five months after the strategic agreement signed on August 6 last year, the commercialization contract period will be 10 years after the licensing agreement is signed, and after consultation, it will be extended for five years.

According to the company, after approval of the clinical trial plan by the U.S. FDA in July 2020, the phase 2 clinical trial began on October 8, 2020, and is currently registered as a subject at clinical trial hospitals such as Kansas, New Jersey, Indiana, etc. 174 people) and administration is in progress.

A randomized, placebo-controlled, double-blind, efficacy and safety test for hospitalized patients with mild and moderate pneumonia caused by coronavirus.Phase 2 clinical trial is in progress.If the clinical trial results confirm the anthroquinolol effect and safety, it is urgent to the US FDA. I plan to apply for approval for use.

An official from BNC Korea said, “We hope that the US clinical trial for anthroquinolol, which has proven its safety in clinical trials such as anticancer drugs, and has been shown to have antiviral, anti-inflammatory, and anti-pulmonary fibrosis effects, has been successfully carried out, and is expected to receive emergency use approval “We expect to be able to supply treatment to 4 countries including Korea if we obtain approval for emergency use.”

In addition, “The two companies agreed to a detailed agreement and technology for supply, transportation and manufacturing period, technology transfer, etc. through a final detailed contract, and accordingly, decided to accelerate the commercialization of corona treatment.” “At the Sejong Korea BNC GMP factory, which is currently completed, When PIC/S GMP approval is received, we will manufacture anthroquinolol at BNC Korea manufacturing facility in consultation with Golden Biotech.”

– .